Cabaletta Bio, Inc.
CABAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cabaletta Bio, Inc. focuses on Biotechnology services and products. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. With a market capitalization of $461.4M, it sits in small-cap territory. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Market Cap
$461.4M
Beta
3.26
P/E (TTM)
—
P/E (Fwd)
-1.99
EPS (TTM)
$-1.90
EPS (Fwd)
$-1.42
ROE
-156.0%
ROA
-71.6%
Cash
$116.6M
Total Debt
$26.4M
Free CF
-$90.8M
52W Change
69.5%
Annual Financials
Cash vs Debt
With $116.6M in cash and $26.4M in debt, CABA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$90.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -156.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, CABA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CABA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CABA.